Study reveals reasons for different responses to anti-PD-1 checkpoint blockade immunotherapy
A team of researchers affiliated with Johns Hopkins University and Memorial Sloan Kettering Cancer Center has found some of the reasons for different responses to anti-PD-1 checkpoint blockade immunotherapy in cancer patients. ...